Endo sues Zydus in patent battle over methods of purifying generic version of recalled smoking cessation drug Chantix
10 Aug 2023
Patent Infringement
Endo International, which lost a patent battle last year over its vasopressin injection Vasostrict, is back in court — this time suing Zydus Pharmaceuticals for patent infringement over its generic version of Pfizer’s smoking-cessation drug Chantix.
Endo’s generic drug making subsidiary Par Pharmaceutical filed its complaint on Aug. 8 in Delaware District Court against Zydus, alleging that Zydus’ generic infringes on Endo’s recently-filed patent for how to purify the drug. Endo has also asked for an unspecified amount of damages and that Zydus’ generic be taken off of the market.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.